Uromigos Live 2023-Renal Cell Carcinoma

The UromigosUromigos Live 2023 | November 20, 2023
Dr. Powles chaired a livestreamed RCC session that included lively discussion from Drs. Atkins, McDermott, and Rini.
View More
The UromigosUromigos Live 2023 | November 20, 2023
The panel highlights a serious of relevant studies in renal cell carcinoma, including CONTACT-03 and TiNivo-2.
Regina Barragan-Carrillo, MDUromigos Live 2023 | November 8, 2023
Dr. Regina Barragán-Carrillo discusses new data in the IO-refractory RCC setting that were presented during the RCC panel.
Scott Haake, MD, PhDUromigos Live 2023 | November 8, 2023
Scott Haake, MD, PhD, discusses his favorite frontline ccRCC data that were presented at Uromigos Live.
Benjamin Garmezy, MDUromigos Live 2023 | November 8, 2023
Benjamin Garmezy, MD, discusses what the best treatment strategies may be for RCC and the potential of IO-only strategies.
Monty Pal, MDUromigos Live 2023 | November 8, 2023
Dr. Monty Pal discusses the current IO-refractory RCC space and approaches to patients in the 2nd- and 3rd-line settings.
Katy Beckermann, MD, PhDUromigos Live 2023 | November 8, 2023
Dr. Beckermann shares why there is a need to identify a biomarker for patients with RCC who will benefit from belzutifan.
Renée Saliby, MD, MScUromigos Live 2023 | November 8, 2023
Dr. Saliby shares what she has liked about the RCC panels and how she sees space for new biomarkers and mechanisms of action.
The UromigosThe Uromigos | November 6, 2023
Monty Pal, Toni Chouieri, and Tian Zhang join Tom and Brian to discuss CONTACT-03, TiNivo-2, IO-based therapy, and more.
Michael B. Atkins, MDUromigos Live 2023 | October 16, 2023
Dr. Michael Atkins discusses long-term results of IO/TKI combinations for metastatic RCC and how they may influence debate.
David F. McDermott, MDUromigos Live 2023 | October 5, 2023
Dr. David McDermott from Beth Israel Deaconess Medical Center discusses his favorite Uromigos guests and episodes.
Advertisement
Advertisement